广谱与有限基因面板指导晚期实体瘤患者治疗:一项随机对照试验
这项多中心随机试验在晚期和/或转移性实体瘤患者中,比较324个癌症相关基因面板(Foundation OneCDX)与87个单核苷酸/ indel基因及全基因组拷贝数变异面板(CTL)指导分子匹配治疗的效果。F1CDX组识别分子匹配推荐治疗的患者比例为51.6%(175例),CTL组为36.9%(125例),差异为14.8个百分点(P < 0.001),达到主要终点;但两组临床结局无差异。
要点
- F1CDX组识别MBRT的患者比例为51.6%,CTL组为36.9%,提高14.8个百分点(P < 0.001)。
- 在需要超越标准基因组改变治疗的患者中,两组临床结局无差异。
- 更广泛的基因面板可增加分子匹配治疗的数量,但需更大规模研究评估临床获益。
核心结论
- 更广泛的基因面板可增加分子匹配治疗的数量,但在这项试验中未观察到临床结局差异。
- 需要更大规模的研究来评估扩展分子匹配推荐治疗的临床获益。
研究设计与样本
- 多中心随机对照试验,纳入晚期和/或转移性实体瘤患者。
- 筛查741例患者,其中45.7%具有质量检查合格的肿瘤样本。
- 使用Foundation OneCDX(F1CDX,324个癌症相关基因面板)或CTL(87个单核苷酸/ indel基因及全基因组拷贝数变异面板)确定分子改变,并由分子肿瘤委员会审查以识别分子匹配推荐治疗(MBRT)。
- 主要终点为识别出MBRT的患者比例,使用每位患者两种面板的配对数据。
主要发现
- F1CDX组识别MBRT的患者为175例(51.6%),CTL组为125例(36.9%)。
- 与更有限的面板相比,更全面的基因面板使MBRT识别率显著增加14.8个百分点(P < 0.001),达到主要终点。
- 在这些需要超越标准基因组改变治疗的晚期和/或转移性癌症患者中,未观察到临床结局差异。
关键数值与推荐
- F1CDX组识别MBRT比例51.6%(175例) vs CTL组36.9%(125例),F1CDX较CTL提高14.8个百分点(P < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更大规模的研究来评估扩展MBRT的临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Large genomic programs have contributed to improving drug development in cancer. To assess the potential benefit of using larger gene panels to guide molecular-based treatments, we conducted a multicenter randomized trial in patients with advanced and/or metastatic solid cancer. Molecular alterations were determined using either a panel of 324 cancer-related genes (Foundation OneCDX (F1CDX)) or a limited panel of 87 single-nucleotide/indel genes and genome-wide copy number variations (CTL) and reviewed by a molecular tumor board to identify molecular-based recommended therapies (MBRTs). Using paired data from both panels for each patient, the primary endpoint was the proportion of patients with an MBRT identified. Main secondary endpoints included the number of patients with at least one actionable alteration leading to MBRT identification, the number of patients with and without MBRTs initiated, progression-free survival, best overall response, duration of response and safety. Among the 741 patients screened, 45.7% had quality-checked tumor samples. MBRTs were identified with F1CDX in 175 (51.6%) patients and with CTL in 125 (36.9%) patients, translating to a significant increase of 14.8 percentage points (P < 0.001) with the more comprehensive gene panel versus the more limited panel, meeting the primary endpoint. However, no differences in clinical outcomes were observed in these patients with advanced and/or metastatic cancer in need of treatment beyond standard genomic alterations. These findings illustrate the potential for larger gene panels to increase the number of molecularly matched therapies. Larger studies are needed to assess the clinical benefit of expanded MBRTs. ClinicalTrials.gov registration: NCT03163732 .
引用
- Trédan O, Pouessel D, Penel N, et al. Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial. Nat Med. 2025. PMID: 40195451. doi:10.1038/s41591-025-03613-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。